SLC5A2 and diabetes mellitus: In addition, more patients on SGLT2 inhibitors had disease duration of less than 5 years (31% vs. 21%) and fewer DM complications prior to treatment initiation (e.g. 2% vs. 14% for DM-kidney complications).